Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

This study is testing whether a drug that targets a protein called TIM-3 on immune cells (called RAK cells) can prevent liver cancer from returning after surgery. The aim is to boost the immune system's ability to detect and destroy any remaining cancer cells. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by biopsy - You have had surgery to completely remove your liver cancer - Your cancer met certain higher-risk features: tumor ≥5 cm, microscopic blood vessel invasion, satellite nodules, multiple tumors, elevated AFP marker, or capsule invasion - Your liver function and overall health are within acceptable ranges (ECOG score 0–1, Child-Pugh A or B) - Your estimated survival is more than 6 months **You may NOT be eligible if...** - Your liver cancer has returned or spread before surgery - Your liver function, heart function, or blood counts are too low to tolerate treatment - You are pregnant or planning to become pregnant during the study Talk to your doctor to see if this trial is right for you.